Dr. Marie Louise Fox, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 6101 Newport Rd, Ste A, Portage, MI 49002 Phone: 269-382-6500 Fax: 269-382-2286 |
Laura H Mitchell, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 6650 S Westnedge Ave, Ste 232 Crossroads Mall, Portage, MI 49024 Phone: 269-327-2881 Fax: 269-327-9253 |
Dr. Jeffery Clinton Cosgrove, O.D. Optometrist - Corneal and Contact Management Medicare: Not Enrolled in Medicare Practice Location: 1905 Lakeview Dr, Portage, MI 49002 Phone: 269-323-4605 |
Natasha Switchuk, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 6800 S Westnedge Ave Ste E, Portage, MI 49002 Phone: 269-216-5912 |
News Archive
Is the indefinite expansion of adult cells possible without recourse to stem cell intermediates? The team led by Michael Sieweke at the Centre d'immunologie de Marseille Luminy (Université Aix-Marseille 2 / CNRS / INSERM) has proved that this is the case by achieving the ex vivo regeneration for several months of macrophages, specialized cells in the immune system.
Obesity and severe obesity in childhood and adolescence have been added to the list of conditions that put children and teens at increased risk for premature heart disease, according to a new scientific statement from the American Heart Association published in the Association's journal Circulation.
Omeros Corporation today announced that it recently submitted a Marketing Authorization Application to the European Medicines Agency seeking approval to market OMS302 for use in patients undergoing intraocular lens replacement surgery in the European Union.
During a regular annual physical exam, blood is usually drawn to check the health of a person's heart, kidneys and liver. Now, researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center say a blood test that detects the early development of emphysema - well before symptoms occur - may someday also be offered.
Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, today announced the publication of results from a randomized-controlled clinical trial of the bulking agent, NASHA DX, a dextranomer suspended in stabilized, which was injected into the submucosa of the anal canal in patients with fecal incontinence.
› Verified 3 days ago